Viz HCM vs Viz RV/LV
AI Verdict
Choose Viz HCM if…
Choose Viz HCM if your institution prioritizes early and efficient detection of Hypertrophic Cardiomyopathy (HCM) directly from ECGs. This tool is ideal for cardiology departments and emergency medicine seeking to significantly reduce diagnosis time and automate the coordination of care for suspected HCM patients. It streamlines workflows by providing real-time alerts and directing patients to appropriate specialists.
View Viz HCM →Choose Viz RV/LV if…
Choose Viz RV/LV if your emergency department or radiology group needs rapid, automated risk stratification for suspected pulmonary embolism (PE) using CTPA scans. This tool is best suited for environments where quick assessment of right ventricular strain is critical for guiding immediate treatment decisions and enhancing care coordination within a broader PE management solution. It provides crucial RV/LV ratio measurements to inform clinical pathways.
View Viz RV/LV →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz RV/LVBoth tools offer seamless integration with existing clinical workflows, EHR, and PACS systems, along with mobile-based alerts for care coordination. However, Viz RV/LV specifically highlights a 'High-fidelity mobile DICOM image viewer' for CTPA scans, which provides a specialized and enhanced user experience crucial for radiologists and emergency physicians reviewing complex imaging on the go.
Clinical Value
Viz HCMBoth are FDA-cleared and clinically validated for critical conditions. Viz HCM addresses Hypertrophic Cardiomyopathy, a condition where nearly 85% of patients are undiagnosed or misdiagnosed, and studies show it significantly reduces diagnosis time from years to a mean of 37 days and identifies new cases years earlier. This profound impact on a largely undiagnosed, life-threatening condition gives it a slight edge in demonstrated clinical value.
Pricing & Value
Viz HCMViz HCM offers transparent pricing details, stating it is subscription-based for hospitals and health systems, with CMS reimbursement available for specific CPT codes (0764T and 0765T) effective January 1, 2025, at a national payment rate of $128.90. In contrast, Viz RV/LV's pricing is not publicly available, making it difficult for potential customers to assess its value proposition without direct vendor contact.
Enterprise Readiness
TieBoth tools are developed by Viz.ai and leverage the same underlying cloud-based platform, ensuring HIPAA compliance, BAA availability, and robust integration capabilities with EHR and PACS systems. Viz.ai's platform is extensively deployed across thousands of hospitals globally, demonstrating proven enterprise-grade security, scalability, and operational rigor for both solutions.
Innovation
Viz HCMBoth tools utilize AI for innovative diagnostic assistance. However, Viz HCM stands out as the first and only FDA-cleared AI algorithm for real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy, a complex and often missed diagnosis. This application of AI to ECGs for early detection of a historically challenging condition represents a more significant and novel breakthrough.
Support & Docs
TieAs both tools are products of Viz.ai, they share the same comprehensive customer support infrastructure. Viz.ai provides dedicated customer success teams, clinical and workflow specialists, 24/7 on-call clinical specialists, implementation experts, and a centralized knowledge base with various resources. There is no information to suggest a difference in the level or quality of support and documentation between the two specific tools.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Viz HCM | Viz RV/LV |
|---|---|---|
| Tool Name | Viz HCM | Viz RV/LV |
| Primary Detection Method | AI-powered ECG analysis for Hypertrophic Cardiomyopathy (HCM) detection; Real-time disease detection from electrocardiograms | AI algorithm for automated Right Ventricle (RV) to Left Ventricle (LV) ratio measurement from CTPA scans; Analysis of volumetric CTPA acquisitions |
| Target Condition/Measurement | Suspected Hypertrophic Cardiomyopathy (HCM) | RV/LV ratio for rapid pulmonary embolism risk stratification |
| Key Specialties Supported | Cardiology, Emergency Medicine, Hospital Medicine | Emergency Medicine, Pulmonology, Radiology |
| Care Coordination Features | Mobile-based alerts and notifications to multidisciplinary care teams; Automated direction of patients to appropriate care specialists; Streamlines cardiac care coordination and clinical workflows | AI-powered alerts and notifications to care teams; HIPAA-compliant communication platform for care coordination |
| Integration | Integrated into hospital IT systems (EHR, PACS); Seamless integration with existing clinical workflows, EHR, and PACS systems | Seamless component of the Viz PE Solution |
| Company | Viz.ai | Viz.ai |
Videos
Demos, reviews, and walkthroughs featuring Viz HCM and Viz RV/LV.
Frequently Asked Questions
More Comparisons
More matchups featuring Viz HCM or Viz RV/LV
Backers
Who funded each tool's parent company.